The company has not filed an annual or quarterly report since its Q3 FY2018 10-Q, filed Nov 1, 2018. Its latest SEC filing is a SC 13G from Feb 15, 2019.
10-Q for Q3 FY2018, filed Nov 1, 2018
The sections below describe the company as of the FY2017 annual report.
Develops and sells medicines for people with rare diseases and highly specialized conditions.
10-K for FY2017, filed Feb 20, 2018
Shire sells its own medicines, with product sales tied to delivery, and earns royalties and other revenue, including upfront payments, from products it licenses to other companies.
10-K for FY2017, filed Feb 20, 2018Company revenues, expenditures and net assets are attributable to the R&D, manufacture, sale and distribution of pharmaceutical products…View ↗
Revenues are derived primarily from two sources - sales of the Company’s own products and royalties and other revenues:View ↗
95.3% (2016: 95.5%) of total revenues are derived from Product sales; and 4.7% (2016: 4.5%) of total revenues are derived from royalties…View ↗
Revenues from Product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery.…View ↗
$15.2B
10-K for FY2017, filed Feb 20, 2018
$15.2B ↗
Its medicines are for people with rare diseases and specialized conditions; physicians, patients and insurers are among the decision-makers whose acceptance affects commercial success.
10-K for FY2017, filed Feb 20, 2018
Yes. It kept 28 cents of every revenue dollar as net income in .
10-K for FY2017, filed Feb 20, 2018
10-Q for Q3 FY2018, filed Nov 1, 2018
$537.2MView ↗
8-K, filed Jan 8, 2019
Completion of Acquisition or Disposition of Assets.View ↗
Broader treatment areas
The latest report says the Baxalta acquisition added business in blood disorders, immune conditions and cancer; the earlier report described commercial units in rare diseases, neuroscience, gastrointestinal and internal medicine.
10-K for FY2017, filed Feb 20, 2018 10-K for FY2014, filed Feb 24, 2015The acquisition of Baxalta in June 2016 added the Hematology, Immunology and Oncology franchises and enabled Shire to become the global…View ↗
Shire has commercial units that focus exclusively on the commercial execution of its marketed products (the “In-Line” group) in the areas…View ↗
Competes with Pfizer, SOBI, Bayer, CSL, Bioverativ, Novo Nordisk, Octapharma, Alnylam, Roche, Genentech, Biomarin, Spark, Sangamo, Pharmstandard, LFB Group, Genzyme, Amicus, Isu Abaxis, Protalix, and Actelion
10-K for FY2017, filed Feb 20, 2018The principal sources of competition for ADVATE and ADYNOVATE globally are: XYNTHA/REFACTO AF (Pfizer and SOBI); KOGENATE (Bayer); HELIXATE…View ↗
Loading...
